Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphenhydramine + zolpidem
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Topical, Rectal
01
Overview
Di **Diphenhydramine + zolpidem** is a combination of two pharmaceutical drugs: diphenhydramine and zolpidem. Diphenhydramine is a first-generation H1 receptor antagonist (antihistamine) primarily used for treating allergies and as an over-the-counter sleep aid due to its sedative properties. Zolpidem is a non-benzodiazepine hypnotic that acts as a GABA-A receptor agonist and is FDA approved for the short-term treatment of insomnia. When combined, these drugs significantly increase central nervous system depression, leading to enhanced sedation, dizziness, and risk of confusion, especially in older adults. No unique branded combination exists under this name; their co-administration is generally discouraged due to a high risk of adverse effects[1][2][4].
- Other names
- diphenhydramine / zolpidem
02
Targets
mAChR (Muscarinic acetylcholine receptors)GABRR (GABA-A receptor subunit rho)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on diphenhydramine + zolpidem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphenhydramine + zolpidem.